Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
about
Olmesartan-associated enteropathy.Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanomaVaccine strategies for glioblastoma: progress and future directions.Complications of targeted drug therapies for solid malignancies: manifestations and mechanismsIatrogenic pathology of the intestines.The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.[Treatment side effects and follow-up of malignant melanoma].Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?Immune-related tumor response assessment criteria: a comprehensive review.Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.[Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging.Q56897679
P2860
Q33788785-083CC34B-D049-448F-BB7E-ABCC1AB39CD3Q35668604-A889DC13-829D-463B-8365-C6A1D9487966Q36132702-7AB6D8C0-0495-4A88-ADFF-BC91083B636EQ36879912-DD179D30-0033-4F2E-A314-D1C29A1CAA6CQ37589557-9F9D7AE8-B171-4EC4-B8E4-42A2517E3C3FQ37985890-93322CB7-3773-4E87-B72B-EB05564A24CAQ38081910-1E538F06-65F3-4540-A746-1C2687EBB6B1Q38084265-F6361319-420F-463F-88D4-2C86B4A16C09Q38339456-143FA46A-E301-460F-8A50-5FB22585FE2CQ39227781-24326D12-2A3C-4427-8090-78D509AAE585Q40004066-2D02CD1A-4D84-4F69-8CCF-C18059F4BACBQ41516358-CB818F5D-D82A-450E-B0C1-ADE93AB2D425Q41669891-6F5ADE3D-1007-4E60-B37B-AFFCB50740AFQ43838521-14B2E6F8-1E38-42C7-944D-826E846CA59FQ49668388-A6955ECB-8D75-4DD9-80A7-8328671F01FBQ50089384-52C29420-F84B-419C-A16D-EA647CD89794Q50746463-05C8C4B7-E06B-4E85-B7CE-C165D4E03EC8Q53060188-8232AED7-8C29-4A4D-ADF5-2391DFE6D915Q56897679-FBB3B434-92AB-4F1F-A078-06385C058235
P2860
Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Radiologic aspects of immune-r ...... undergoing ipilimumab therapy.
@en
Radiologic aspects of immune-r ...... undergoing ipilimumab therapy.
@nl
type
label
Radiologic aspects of immune-r ...... undergoing ipilimumab therapy.
@en
Radiologic aspects of immune-r ...... undergoing ipilimumab therapy.
@nl
prefLabel
Radiologic aspects of immune-r ...... undergoing ipilimumab therapy.
@en
Radiologic aspects of immune-r ...... undergoing ipilimumab therapy.
@nl
P2093
P356
P1476
Radiologic aspects of immune-r ...... undergoing ipilimumab therapy.
@en
P2093
F Stephen Hodi
Jyothipriya P Jagannathan
Kevin N O'Regan
Nikhil Ramaiya
P304
P356
10.2214/AJR.10.6032
P407
P577
2011-08-01T00:00:00Z